Trial · NCT01999179
Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis
NCT01999179, Not applicable, Completed, Medical College of Wisconsin; results first posted 2021-12-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis. Trials, record NCT01999179. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01999179
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis
- NCT number
- NCT01999179
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 27 participants, actual
- Lead sponsor
- Medical College of Wisconsin
- Conditions
- Venous Thrombosis, Neoplasms
- Interventions
- Heparin, Low-Molecular-Weight, or direct oral anticoagulants
- First posted
- 2013-12-03
- Last updated
- 2022-05-18
- Results first posted
- 2021-12-22
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PTS Assessment Completion | 1 year | Percentage of participants who completed post-thrombotic syndrome assessments |
| Secondary | Biomarker Sample Collection | 1 year | Number of participants that completed sample collection for biomarker analysis to predict recurrent venous thrombosis |
| Other | Number of Participants With Post-thrombotic Syndrome | 6 months after catheter removal | The number of participants with post-thrombotic syndrome 6 months after catheter removal in cancer patients with catheter-related thrombosis treated with 1 month of anticoagulation |
| Other | Number of Participants With Recurrent Thrombosis | 6 months after catheter removal | Number of participants with recurrent thrombosis in cancer patients with catheter-related thrombosis treated with 1 month of anticoagulation |
| Other | Number of Participants With Major Bleeding | 6 months after catheter removal | Number of participants with major bleeding in cancer patients with catheter-related thrombosis treated with 1 month of anticoagulation |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | PTS Assessment Completion | 1 year | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Biomarker Sample Collection | 1 year | participants | NUMBER | |
| OTHER_PRE_SPECIFIED | Number of Participants With Post-thrombotic Syndrome | 6 months after catheter removal | Participants | COUNT_OF_PARTICIPANTS | |
| OTHER_PRE_SPECIFIED | Number of Participants With Recurrent Thrombosis | 6 months after catheter removal | Participants | COUNT_OF_PARTICIPANTS | |
| OTHER_PRE_SPECIFIED | Number of Participants With Major Bleeding | 6 months after catheter removal | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| PTS Assessment Completion | Low-molecular-weight Heparin or Direct Oral Anticoagulant | 17 | Participants | ||
| Biomarker Sample Collection | Low-molecular-weight Heparin or Direct Oral Anticoagulant | 7 | participants | ||
| Number of Participants With Post-thrombotic Syndrome | Low-molecular-weight Heparin or Direct Oral Anticoagulant | 0 | Participants | ||
| Number of Participants With Recurrent Thrombosis | Low-molecular-weight Heparin or Direct Oral Anticoagulant | 0 | Participants | ||
| Number of Participants With Major Bleeding | Low-molecular-weight Heparin or Direct Oral Anticoagulant | 1 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Low-molecular-weight Heparin or Direct Oral Anticoagulant | 27 | |
| Overall Study | COMPLETED | Low-molecular-weight Heparin or Direct Oral Anticoagulant | 20 | |
| Overall Study | NOT COMPLETED | Low-molecular-weight Heparin or Direct Oral Anticoagulant | 7 |
Source ClinicalTrials.gov
Adverse events3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Bleeding | Blood and lymphatic system disorders | Low-molecular-weight Heparin or Direct Oral Anticoagulant | 2 | 27 | |
| other | Fall | General disorders | Low-molecular-weight Heparin or Direct Oral Anticoagulant | 2 | 27 | |
| serious | Hematoma | Musculoskeletal and connective tissue disorders | Low-molecular-weight Heparin or Direct Oral Anticoagulant | 1 | 27 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Low-molecular-weight Heparin or Direct Oral Anticoagulant | 0 | 27 |
| Total, other adverse events | Low-molecular-weight Heparin or Direct Oral Anticoagulant | 2 | 27 |
| Total, serious adverse events | Low-molecular-weight Heparin or Direct Oral Anticoagulant | 1 | 27 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01999179
GET https://conductscience.org/api/trials/v1/NCT01999179/registered